SG156668A1 - Angiopoietin-2 specific binding agents - Google Patents

Angiopoietin-2 specific binding agents

Info

Publication number
SG156668A1
SG156668A1 SG200907008-7A SG2009070087A SG156668A1 SG 156668 A1 SG156668 A1 SG 156668A1 SG 2009070087 A SG2009070087 A SG 2009070087A SG 156668 A1 SG156668 A1 SG 156668A1
Authority
SG
Singapore
Prior art keywords
angiopoietin
specific binding
binding agents
antibodies
disclosed
Prior art date
Application number
SG200907008-7A
Other languages
English (en)
Inventor
Jonathon Daniel Oliner
Kevin Graham
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/982,440 external-priority patent/US7658924B2/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG156668A1 publication Critical patent/SG156668A1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200907008-7A 2004-10-19 2005-10-19 Angiopoietin-2 specific binding agents SG156668A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62016104P 2004-10-19 2004-10-19
US10/982,440 US7658924B2 (en) 2001-10-11 2004-11-04 Angiopoietin-2 specific binding agents

Publications (1)

Publication Number Publication Date
SG156668A1 true SG156668A1 (en) 2009-11-26

Family

ID=39608222

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200907008-7A SG156668A1 (en) 2004-10-19 2005-10-19 Angiopoietin-2 specific binding agents

Country Status (10)

Country Link
JP (2) JP2008520188A (enrdf_load_stackoverflow)
CN (1) CN101495513B (enrdf_load_stackoverflow)
BR (1) BRPI0518209A (enrdf_load_stackoverflow)
EA (1) EA011866B1 (enrdf_load_stackoverflow)
IL (1) IL182279A0 (enrdf_load_stackoverflow)
MA (1) MA29015B1 (enrdf_load_stackoverflow)
MX (1) MX2007004247A (enrdf_load_stackoverflow)
RU (2) RU2404992C2 (enrdf_load_stackoverflow)
SG (1) SG156668A1 (enrdf_load_stackoverflow)
ZA (1) ZA200704020B (enrdf_load_stackoverflow)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA011866B1 (ru) * 2004-10-19 2009-06-30 Амджен Инк. Агенты, специфически связывающие ангиопоэтин-2
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EA022546B1 (ru) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Способ торможения роста карциномы эрлиха у лабораторного животного
JP2014532053A (ja) * 2011-09-30 2014-12-04 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 治療用ペプチド
NZ627859A (en) * 2012-01-23 2015-09-25 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
WO2014100834A1 (en) * 2012-12-21 2014-06-26 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity
CN105264380B (zh) 2013-05-14 2017-09-05 卫材R&D管理有限公司 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
AU2015309862C1 (en) 2014-08-28 2020-10-15 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
DK3263106T3 (da) 2015-02-25 2024-01-08 Eisai R&D Man Co Ltd Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
MX381976B (es) 2015-08-20 2025-03-13 Eisai R&D Man Co Ltd Agente terapéutico contra tumores.
CN106512006A (zh) * 2016-07-25 2017-03-22 广州道瑞医药科技有限公司 Angpt2分泌抑制剂在制备用于治疗血管瘤的药物中的应用
CN106075448A (zh) * 2016-07-25 2016-11-09 广州道瑞医药科技有限公司 Angpt2抑制剂在制备用于治疗血管瘤的药物中的应用
ES2971448T3 (es) 2017-02-08 2024-06-05 Eisai R&D Man Co Ltd Composición farmacéutica para el tratamiento de tumores
SG11201910100PA (en) 2017-05-16 2019-11-28 Eisai R&D Man Co Ltd Treatment of hepatocellular carcinoma
CN109096368B (zh) * 2018-09-30 2021-07-20 华南理工大学 一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用
EP3932946A4 (en) * 2019-02-25 2023-03-22 Pharmabcine Inc. ANTI-ANG2 ANTIBODIES AND ITS USE
CN112126671B (zh) * 2020-08-18 2021-08-31 中山大学附属第五医院 无乳链球菌Streptococus agalactiae治疗子宫内膜异位症的应用
CN116265487B (zh) * 2021-12-16 2025-01-10 三优生物医药(上海)有限公司 抗ang2-vegf双特异性抗体及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1165115B1 (en) * 1999-03-26 2003-05-28 Regeneron Pharmaceuticals, Inc. Modulation of vascular permeability by mean of tie2 receptor activators
WO2000064946A2 (en) * 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
EE200200706A (et) * 2000-06-23 2004-06-15 Schering Aktiengesellschaft VEGF-i/VEGF-retseptori ja angiopoetiini/Tie-retseptori funktsiooni mõjustavad kombinatsioonid ja kompositsioonid ning nende kasutamine (II)
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
ATE536868T1 (de) * 2001-10-12 2011-12-15 Monosolrx Llc Einheitliche filme als schnell auflösende verabreichungsformen enthaltend geschmacksmaskiereden stoff
EA011866B1 (ru) * 2004-10-19 2009-06-30 Амджен Инк. Агенты, специфически связывающие ангиопоэтин-2

Also Published As

Publication number Publication date
MA29015B1 (fr) 2007-11-01
IL182279A0 (en) 2007-07-24
EA200700876A1 (ru) 2007-10-26
JP2011207882A (ja) 2011-10-20
CN101495513A (zh) 2009-07-29
CN101495513B (zh) 2014-08-06
RU2404992C2 (ru) 2010-11-27
EA011866B1 (ru) 2009-06-30
ZA200704020B (en) 2008-06-25
RU2007118670A (ru) 2008-12-27
RU2010132956A (ru) 2012-02-10
BRPI0518209A (pt) 2008-11-04
JP2008520188A (ja) 2008-06-19
MX2007004247A (es) 2007-06-12

Similar Documents

Publication Publication Date Title
RS28904A (en) Angiopoietin-2 specific binding agents
MY156458A (en) Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
SG156668A1 (en) Angiopoietin-2 specific binding agents
LUC00025I2 (enrdf_load_stackoverflow)
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
EA200400526A1 (ru) Агенты, специфически связывающиеся с человеческим ангиопоэтином-2
WO2012047583A3 (en) Antibodies binding human collagen ii
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
WO2006085938A3 (en) Il-13 binding agents
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
EP2192132A3 (en) Anti-IL-20, anti-IL22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
TW200635946A (en) Binding proteins specific for human matriptase
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
MX2007013108A (es) Reactivos que enlazan ccx-ckr2.
WO2006029220A3 (en) Combination therapy with anti-ctla4 and anti-4-1bb antibodies
WO2007076465A3 (en) Cln248 antibody compositions and methods of use
WO2006013462A3 (en) Growth factors nsg28, nsg30, and nsg32
MX360580B (es) Autoanticuerpos humanos anti-alfa-sinucleina.